Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of TQB2102 versus docetaxel + trastuzumab + pertuzumab in HER2-positive recurrent or metastatic breast cancer
CTR20252113Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2102 in breast cancer, sponsored by Nanjing Shunxin Pharmaceutical. Started Jan 2026; status: active.
02
Drugs
TQB2102
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20252113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252113.